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Abstract
The function of cyclin D1 as a positive regulator of the cell cycle and proto-oncogene has been well
established. Cyclin D1 elicits its pro-proliferative function early in G1 phase, through its ability to
activate cyclin dependent kinase (CDK) 4 or 6. Active CDK4/6-cyclin D1 complexes phosphorylate
substrates that are critical for modulating G1 to S phase progression, and in this manner promote
cellular proliferation. Emerging data from a number of model systems revealed that cyclin D1 also
holds multiple, kinase-independent cellular functions. First, cyclin D1 assists in sequestering CDK
inhibitors (e.g. p27kip1), thus bolstering late G1 CDK activity. Second, cyclin D1 is known to bind
and modulate the action of several transcription factors that hold significance in human cancers.
Thus, cyclin D1 impinges on several distinct pathways that govern cancer cell proliferation.
Although intragenic somatic mutation of cyclin D1 in human disease is rare, cyclin D1 gene
translocation, amplification and/or overexpression are frequent events in selected tumor types.
Additionally, a polymorphism in the cyclin D1 locus that may affect splicing has been implicated in
increased cancer risk or poor outcome. Recent functional analyses of an established cyclin D1
splice variant, cyclin D1b, revealed that the cyclin D1b isoform harbors unique activities in cancer
cells. Here, we review the literature implicating cyclin D1b as a mediator of aberrant cellular
proliferation in cancer. The differential roles of cyclin D1 and the cyclin D1b splice variant in
prostate cancer will be also be addressed, wherein divergent functions have been linked to altered
proliferative control.
Background
Cyclin D1 is a focal point for integrating mitogenic stim-
ulation with cellular proliferation [1,2]. Mitogenic signals
typically induce increases in cyclin D1 mRNA expression
and translation, thereby increasing the cellular pool of the
protein product. The pro-proliferative function of cyclin
D1 is mediated through its ability to regulate the cell cycle
machinery, and excessive cyclin D1 expression and/or
activity is a hallmark of several tumor types [3,4]. In addi-
tion, cyclin D1 has cell cycle-independent functions
through its ability to modulate transcription factor action
[5]. Given the importance of cyclin D1 in human disease,
concerted effort has been directed at delineating the
mechanisms by which cyclin D1 is dysregulated in cancer.
In selected tumor types, cyclin D1 is overexpressed as a
result of chromosomal translocation or amplification of
the cyclin D1 (CCND1, PRAD) locus [1,6]. Intragenic
somatic mutations of cyclin D1 are rare, but a polymor-
phism of cyclin D1 that occurs in a splice donor site has
been epidemiologically linked to increased cancer risk or
poor prognosis in a number of tumor types (reviewed in
[7]). Recent functional analyses have revealed that the
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protein product of an alternately spliced transcript, cyclin
D1b, harbors overlapping but distinct functions as com-
pared to full length cyclin D1. Herein, the potentially
unique functions of cyclin D1b in cancer are discussed,
with an eye to the future for addressing the mechanism
and consequence of cyclin D1b expression in human dis-
ease.
Mitogen regulation of cyclin D1 expression and stability
Given the importance of cyclin D1 in modulating cellular
proliferation, it is not surprising that cyclin D1 expression
is stringently regulated [1,3]. Growth factor stimulation
typically activates cyclin D1 mRNA production, as can be
achieved through direct induction of the cyclin D1 pro-
moter [8,9]. Several sequence specific transcription factors
have been shown to modulate cyclin D1 promoter activity
in response to mitogens, including peptide growth factors
and steroidal hormones [10]. However, the molecular
effectors of cyclin D1 locus modulation can be tissue spe-
cific. For example, in mammary epithelial or breast cancer
cells, cyclin D1 mRNA expression can be regulated by
estrogen receptor alpha (ER) binding to regulatory regions
within the cyclin D1 locus. It was initially determined that
ER tethers to Sp1 in the proximal cyclin D1 locus to stim-
ulate cyclin D1 mRNA production [11,12]. However,
recent analyses revealed that the ability of estrogen to
induce cyclin D1 in breast cancer cells can be executed
though an enhancer region downstream of the cyclin D1
coding region, and involves recruitment of ERβ to that
locus (M. Brown, personal communication). By contrast,
in colon cancer cells, the Wnt pathway is a key determi-
nant of cyclin D1 expression, and this action is mediated
through β-catenin/TCF [13]. Thus, cyclin D1 mRNA accu-
mulation is coordinated by distinct transcription factors,
dependent on differential mitogen function and tissue
specific cellular milieu.
Once produced, the cyclin D1 transcript is subjected to
multiple modes of post-transcriptional control, including
regulation at the level of mRNA stability, mRNA transla-
tion, subcellular protein localization, and targeted protein
degradation [1,3,14]. Stability of the cyclin D1 transcript
is regulated through 3' UTR regions and/or through asso-
ciation with RNA binding proteins HuR and AUF1 [15-
17]. Transcript destabilization occurs through activation
of divergent signaling agents (e.g. prostaglandins and
rapamycin) [18,19], whereas oncogenic stimuli such as
Wnt/β-catenin stabilize the cyclin D1 mRNA [20]. The
transcript is also subjected to translational control. For
example, PKC-alpha represses cellular proliferation in
part through its ability to block cap-dependent initiation
of cyclin D1 translation in intestinal epithelia [21]. In
many tumor types, the eukaryotic translation initiation
factor eIP4e is dysregulated, and functions to induce cyc-
lin D1 translational efficiency [22]. Thus, regulation of the
cyclin D1 transcript and subsequent protein synthesis rep-
resent major modes of proliferative control.
Ultimately, the cyclin D1 protein is translocated into the
nucleus to exert its pro-proliferative function in G1 phase
of the cell cycle [14]. Subsequently, cyclin D1 is phospho-
rylated on threonine 286; this event facilitates CRM1 rec-
ognition of the phosphoprotein, and subsequent nuclear
export and degradation [23]. The importance of nuclear
export control for appropriate cellular proliferation is evi-
dent, in that cyclin D1 mutants incapable of thr286 phos-
phorylation and nuclear export have markedly enhanced
oncogenic potential, and transgenic expression induces B-
cell lymphoma in murine models [23,24]. Somatic muta-
tions of this residue have been identified in endometrial
and esophageal cancers, thus indicating that disruption of
cyclin D1 nuclear export may participate in tumor devel-
opment and/or progression in this tissue [25,26]. As with
many of the cyclins, regulated degradation also governs
cyclin D1 action. The C-terminus of cyclin D1 contains a
PEST domain, which was hypothesized to act as a degra-
dation motif, but the contribution of this motif for cyclin
D1 destruction has yet to be rigorously demonstrated.
Although the mechanisms remain elusive, ubiquitin-
mediated cyclin D1 degradation can be induced by a myr-
iad of anti-mitogenic signals, including DNA damage
[27,28]. Interestingly, DNA damage-mediated cyclin D1
destruction can occur in the nucleus, indicating that
nuclear export is not always required for cyclin D1 turno-
ver [27]. Combined, these observations indicate that the
cyclin D1 protein is stringently controlled, wherein
mitogens generally act to induce and/or stabilize the pro-
tein, and anti-mitogenic signals dampen cyclin D1 accu-
mulation.
Cyclin D1b: the product of an alternate splicing event
Cyclin D1 is encoded by 5 exons, and harbors distinct
motifs that exert its biological function (Figure 1). In
1995, Betticher et al. described a cyclin D1 variant, now
termed cyclin D1b, which results from alternate splicing
at the exon 4, intron 4 boundary [29]. The location of the
alternate splicing event generated significant interest, as
the splice donor site encompasses a known polymor-
phism of cyclin D1 that has been associated with
increased cancer risk and/or poor prognosis in a multi-
tude of tumor types. The polymorphic residue (G/A870)
is silent for amino acid sequence, but the "A" allele was
hypothesized to reduce the efficacy of the splice donor site
and favor production of an alternate transcript encoding
cyclin D1b. The relationship of the G/A870 polymor-
phism to the production of cyclin D1b has been recently
reviewed [7], and conservative assessment of the estab-
lished data reveals that while the A/A genotype may pre-
dispose to cyclin D1b production, additional factors
contribute to the production of this variant. Most recently,Cell Division 2006, 1:15 http://www.celldiv.com/content/1/1/15
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SWI/SNF chromatin remodeling enzymes have been
implicated in modifying splicing of the cyclin D1 mRNA
[30]. These observations indicate that cyclin D1 splicing
may represent another dynamic mechanism to regulate
cyclin D1 function, and further investigation is needed to
reveal the cadre of variables that impinge on the splicing
event.
Failure to splice at the exon 4/intron 4 boundary results in
complete loss of exon 5 encoded sequences and the acqui-
sition of a novel 33 amino acid stretch at the C-terminal
end, as contributed by translation into intron 4 and the
presence of an intronic stop codon. It is notable that cyc-
lin D1b lacks both the C-terminal PEST sequence and
thr286 residue; lack of these domains predict that the pro-
tein would reside in the nucleus and be intrinsically more
stable than full-length cyclin D1. Interrogation of these
hypotheses validated the first prediction, in that immu-
nostaining for cyclin D1b or the use of GFP-tagged cyclin
D1b revealed the protein to be largely nuclear in localiza-
tion [31,32]. These preliminary observations underscore
the need to carefully evaluate cyclin D1 expression in
tumors, taking into account that many available antisera
fail to recognize the cyclin D1b isoform. Moreover, con-
sideration of cellular compartment may be of importance,
as several studies have shown that cyclin D1 staining in
selected tumor types can be restricted to the cytoplasm
([33-35], and Comstock and Knudsen, in preparation).
Immunohistochemical analyses of cyclin D1 relevance for
prognosis or outcome may need to be re-evaluated for rel-
ative isoform expression and impact dependent on these
parameters.
The second prediction based on cyclin D1b composition
proved incorrect, as cyclin D1b was not significantly more
stable than cyclin D1; rather, half-lives of the two proteins
were similar between the two proteins [31,32]. Therefore,
the inability of cyclin D1b to utilize thr286-driven nuclear
export may not preclude regulated protein degradation.
Interestingly, the nuclear dynamics of the two cyclin D1
isoforms were quite distinct when monitored in living
cells [32]. Full-length cyclin D1 was relatively immobile,
thus indicating that in addition to nuclear export, cyclin
D1 may be regulated by retention into an immobile
nuclear fraction. By contrast, two distinct pools of cyclin
D1b were observed in the nucleus of living cells. The first
population behaved in a manner analogous to cyclin D1,
wherein the protein was largely immobile. The second
population (which constituted approximately one-third
of the total cyclin D1b) showed markedly enhanced
nuclear mobility. Further analyses revealed that cyclin
D1b is highly mobilized in S-phase, thus indicating a dis-
tinct mode of regulation as compared to cyclin D1. The
relative contribution of the mobile versus immobile frac-
tion of cyclin D1b for function has yet to be discerned.
Although many of the functional domains of cyclin D1
are retained within cyclin D1b, subsequent analyses
revealed that cyclin D1b harbors markedly increased
oncogenic function. This unexpected phenomenon was
The cyclin D1 transcript is subject to alternative splicing Figure 1
The cyclin D1 transcript is subject to alternative splicing. Alternative splicing is known to occur at the exon4/intron 4 
boundary. Effective splicing at this junction results in the well-characterized cyclin D1 product (bottom left), which contains 
discrete motifs that regulate cell cycle control, subcellular localization, and transcriptional regulation. Failure to splice at the 
exon4/intron 4 boundary results in the cyclin D1b protein product, which harbors a divergent C-terminus (hatched region). 
The G/A870 polymorphism (circled) is thought to influence the splicing event.Cell Division 2006, 1:15 http://www.celldiv.com/content/1/1/15
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first observed in NIH3T3 cells, wherein cyclin D1b but not
cyclin D1 was sufficient to drive cellular transformation in
vitro (as monitored by focus formation assays) or tumor
formation in vivo [31,32]. Similarly, cyclin D1 null murine
embryo fibroblasts acquired anchorage independence
after restoration of cyclin D1b but not full-length cyclin
D1 [36]. These collective observations suggested that cyc-
lin D1b has enhanced oncogenic potential. Cyclin D1b
has been shown to be expressed in a multitude of cancer
cell types (including mantle cell lymphoma cell lines,
esophageal cancers, B-lymphoid malignancies, prostate
cancer, colon cancer, and breast cancer) [31,37-39], indi-
cating that this heightened oncogenicity may facilitate
tumorigenesis. Interestingly, a sampling of primary man-
tle cell lymphomas revealed that the cyclin D1b transcript
did not result in detectable protein production [40], thus
revealing that the cyclin D1b mRNA or protein may be
under strict regulation in this tumor type. Given the
potency of cyclin D1b in inducing cellular transformation
and tumor formation, concerted effort has been recently
directed at delineating the underlying mechanisms of its
oncogenicity. As discussed hereafter, differential cyclin
D1b functions have been identified for both the cell cycle
and transcriptional regulatory functions normally associ-
ated with cyclin D1.
CDK dependent cell cycle regulation
The role of full-length cyclin D1 as a critical effector of G1-
S progression is well established, and these functions of
cyclin D1 are manifest through modulation of the cell
cycle machinery [1,3,4]. Once produced, cyclin D1 binds
to either cyclin dependent kinase 4 (CDK4) or CDK6,
dependent on cell type, and serves to activate the kinase
moiety (Figure 2). Active cyclin D1-CDK4/6 complexes
phosphorylate a rather limited set of substrates whose
activities play pivotal roles in controlling G1-S progres-
sion [4]. The most well-defined substrate of cyclin D1-
CDK4/6 complexes is the retinoblastoma tumor suppres-
sor protein (RB) [41-43]. In its hypophosphorylated state,
RB exerts potent anti-proliferative action through its abil-
ity to form transcriptional repressor complexes on the
promoters of genes required for S-phase progression
[44,2,45]. CDK mediated phosphorylation of RB relieves
its transcriptional repressor function, and thus promotes
a permissive state for cell cycle progression. The impor-
tance of cyclin D1-CDK4/6 in this process was exempli-
fied in that RB null cells are refractory to the proliferative
action of the cyclin D1-CDK4 complex, and RB deficient
tumor cells often exhibit reduced cyclin D1 dependency
[9,46-48]. Finally, it was shown that the p16ink4a tumor
suppressor, which inhibits cellular proliferation through
its ability to displace cyclin D1 from the CDK4 complex,
is ineffective in RB null cells [46,49,50]. Together, these
data indicated that RB is the principal substrate utilized by
Cell cycle functions of cyclin D1 Figure 2
Cell cycle functions of cyclin D1.Cell Division 2006, 1:15 http://www.celldiv.com/content/1/1/15
Page 5 of 12
(page number not for citation purposes)
full-length cyclin D1-CDK4/6 to modulate G1-S control,
and put forward the hypothesis that the "p16ink4a-cyclin
D1-RB axis" is a key regulator of the mitotic cell cycle. This
hypothesis is borne out in the analyses of human tumors,
wherein over 90% of human tumors show p16ink4a loss,
loss of RB, excessive expression of cyclin D1, or activating
mutation of CDK4 [6]. These aberrations are often tissue
specific, thus indicating that different tumor types favor
differential avenues to disrupt the p16-cyclin D1-RB axis.
Recent reports indicate that cyclin D1-CDK4/6 complexes
phosphorylate additional substrates, including Smad3,
p107, and p130, each of which impinge on cellular prolif-
eration [51,41,52]. Combined, it is hypothesized that the
ability of full-length cyclin D1 to activate CDK4/6 kinase
function is a major mechanism of cell cycle control.
Comparative analyses of cyclin D1b effects on CDK4/6
function and cell cycle proliferation have revealed unex-
pected disparities in function. While cyclin D1b is effi-
cient in CDK4 binding and can induce CDK4 activity in
vitro, it is poorly effective at mediating Rb phosphoryla-
tion in osteosarcoma cells [31,32]. Consistent with this
observation, cyclin D1b was markedly impaired in its
ability to relieve RB-mediated transcriptional repression
at the cyclin A promoter, a key transcriptional target
through which RB governs cell cycle progression [32].
These findings likely underlie the concurrent observation
that cyclin D1b is significantly compromised in its ability
to overcome RB-mediated cell cycle arrest and induce cell
cycle progression, as compared to full-length cyclin D1.
Therefore, although cyclin D1b harbors heightened onco-
genic function, the protein variant appears compromised
in its ability to elicit RB kinase activity and activate cellular
proliferation. It will be of interest to determine whether
the consequence of cyclin D1b expression is dependent
on cell context, as the number of model systems utilized
to assay distinctions between cyclin D1 and cyclin D1b are
limited. Moreover, the relative stoichiometry of each vari-
ant in specific cell types may differentially impinge on cyc-
lin D1b activity, and this parameter should be carefully
considered. For selected tumor types, cyclin D1 has been
postulated as a potential target for therapeutic interven-
tion (e.g. pancreatic and breast cancer) [53-55], and how
the disparate functions of cyclin D1b may influence out-
come should likely be incorporated as a major considera-
tion. The unique mechanisms underlying cyclin D1b
mediated transformation potential are actively under
investigation, and are likely to include non-canonical
effects on the cell cycle machinery as well as cell cycle
independent functions.
CDK4 kinase-independent cell cycle regulation
It is now appreciated that full-length cyclin D1 affects con-
trol over the cell cycle machinery using both kinase-
dependent and kinase-independent mechanisms. For
example, cyclin D1 acts through sequestration of the CDK
inhibitors p21cip1 and p27kip1 to govern G1-S progression
[49,56]. This class of CDK inhibitor predominantly blocks
CDK2 activity, but paradoxically promotes association
(and thus activation) of cyclin D1-CDK4/6 complexes
[57]. The interaction of p21cip1 and p27kip1 with the com-
plex is mediated through direct association with cyclin
D1; thus cyclin D1 indirectly promotes CDK2 activity by
acting as a sink for p21cip1 and p27kip1. Conversely, bind-
ing of p16ink4a to cyclin D1 displaces p21cip1 or p27kip1
and renders these CDK inhibitors free to bind and inhibit
CDK2 activity. Through these mechanisms, full-length
cyclin D1 utilizes both CDK dependent and independent
functions to modulate cell cycle control.
Present studies have yet to address the ability of the cyclin
D1b variant to modulate p21cip1 or p27kip1 activity. The
domain of cyclin D1 that associates with p21cip1 has been
identified (amino acids 20–170) [58], and is retained in
cyclin D1b. It is thereby predicted that cyclin D1b would
maintain the ability to sequester p21cip1 or p27kip1 from
CDK2 complexes. p21cip1 is also known to promote cyclin
D1 nuclear localization through its ability to inhibit GSK-
3β phosphorylation of thr286 [57], but this function
holds no consequence for the cyclin D1b variant. Once
the mechanisms of cyclin D1b-mediated transformation
potential are identified, it will be essential to assess the
impact of CDK inhibitor function on this property.
Cyclin D1 mediated transcriptional control
In the late 1990's an unexpected role for cyclin D1 was
uncovered, as it was established that cyclin D1 interacts
with and modulates a number of transcription factors
whose actions are involved in human cancers (reviewed in
[5]). In general, these functions of cyclin D1 occur
through CDK-independent mechanisms and are manifest
through direct transcription factor binding. One of the
first transcription factors found to associate with cyclin
D1 was estrogen receptor (ER) alpha [59,60], which serves
a critical role in breast cancer development and manage-
ment. These early studies demonstrated that cyclin D1 uti-
lizes an intrinsic "LxxLL" (nuclear receptor association)
motif to enhance ER function, and promote recruitment
of the SRC1 and/or P/CAF co-activators [61,62]. Cyclin
D1 also blocks the ability of BRCA1 to repress ER activity
[63], providing an indirect mechanism of ER activation.
These observations suggested the existence of a positive
feedback loop to control breast cancer cell proliferation,
as ER binds to the cyclin D1 locus and induces cyclin D1
expression [64]. Thus, in breast cancer cells it was pro-
posed that cyclin D1 could use both CDK dependent
mechanisms and CDK independent mechanisms to pro-
mote proliferation. Mice deficient in cyclin D1 but res-
cued with the cyclin D1-KE mutant (defective in CDK4
activation) have normal mammary gland development,Cell Division 2006, 1:15 http://www.celldiv.com/content/1/1/15
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whereas the cyclin D1 null animals are blunted in this
process [65]. These data demonstrate that CDK dependent
functions of cyclin D1 are apparently not required for pro-
liferation and development of murine mammary epithe-
lia. However, both the cyclin D1 nulls and the cyclin D1-
KE mice are unable to support Her2/Neu induced mam-
mary tumor formation, indicating that CDK4 activity is
required for this oncogenic event in mice [65]. In human
breast cancers, gene expression analyses of several hun-
dred specimens showed that transcriptional modulatory
function of cyclin D1 may play an influential role in this
tumor type [66]. Intriguingly, cyclin D1 positive breast
cancers typically exhibit low proliferative rates, and dual
positive immunostaining for ER and cyclin D1 expression
has been associated with positive outcome and/or survival
in some studies [67-70], suggesting that the ability of cyc-
lin D1 to promote ER activity may enhance a differentia-
tive phenotype. Thus, while the relative impact of cyclin
D1 mediated transcriptional control versus CDK4 modu-
lation in breast cancer awaits further investigation, an
abundance of observations support a role for cyclin D1 in
transcriptional control for human tumors.
The ER-modulatory function of cyclin D1 is likely dis-
rupted in the cyclin D1b variant, which lacks the LxxLL
motif required to modulate the receptor. Preliminary
studies support this concept, wherein cyclin D1b induc-
tion yields no significant alteration of ER function (Burd
and Knudsen, unpublished observations). The impact of
this loss of function on breast tumorigenesis or tumor
growth has yet to be examined. However, this variant is
known to be expressed in breast cancer cells [39], and the
polymorphism that may predispose to cyclin D1b produc-
tion has been associated in some (but not all) studies with
increased cancer risk [7,71]. Given the potential link
between dual ER/cyclin D1 expression and outcome, this
parameter may be of significance.
Since the discovery that cyclin D1 can modulate transcrip-
tion factor function, several factors have been established
as targets of full-length cyclin D1 modulation, independ-
ent of CDK function. These factors include STAT3, v-myb,
DMP1, BETA2/Neuro D, and C/EBPβ [66,72-76]. Remark-
ably, the largest class of cyclin D1 mediated transcription
factors is the nuclear receptor superfamily, including ER,
the thyroid hormone receptor (TR), peroxisome prolifera-
tor gamma (PPARγ), and the androgen receptor (AR).
However, the mechanisms and outcome of cyclin D1
action are disparate for the different nuclear receptors.
While cyclin D1 activates ER through its LxxLL motif [61],
cyclin D1 serves as a repressor of TR, PPARγ, and AR func-
tion. The mechanisms utilized to modulate nuclear recep-
tor function are distinct. For TR it was shown that cyclin
D1 associates directly with histone deacetylase (HDAC) 3
but not HDAC1, and recruits this co-repressor to the TR
complex [77]. Some overlap is observed with PPARγ,
wherein cyclin D1 utilizes a defined motif resembling a
helix-loop-helix domain to interact with and block both
ligand-dependent PPARγ activity and PPARγ expression
itself [78,79]. The biological consequence of the cyclin
D1-PPARγ association was validated, in that PPARγ-medi-
ated adipocyte differentiation was enhanced in cyclin D1
-/- fibroblasts, and deletion of cyclin D1 induced PPARγ
expression and activity. The concept that cyclin D1 regu-
lates PPARγ function has additional implications for
breast cancer, wherein PPARγ is known to promote breast
epithelial cell differentiation, and histological analyses of
breast cancer specimens revealed that PPARγ is reduced in
tumors with a high cyclin D1 index [78,80]. Thus, the
ability of cyclin D1 to antagonize PPARγ may alter the
potential anti-proliferative action of PPARγ ligands in this
tissue type. Interestingly, the mechanism of cyclin D1-
mediated PPARγ regulation was attributed to HDAC1 and
HDAC3 recruitment [79]. CDK-dependent mechanisms
may also influence nuclear receptor activity, as active cyc-
lin D1-CDK4 activity is known to cause sequestration of
the GRIP1 nuclear receptor co-activator into inactive, sub-
nuclear structures [81]. Thus, while multiple mechanisms
are implicated as effectors of cyclin D1 function, these
may be nuclear receptor-specific.
Analysis of cyclin D1b expression patterns and conse-
quence for nuclear receptor activity has yet to be fully
established for TR or PPARγ, although it has been shown
that cyclin D1b can repress TR function in transient assays
[37]. The functional domains required for interaction
with both receptors is retained, thus identifying these
receptors as putative targets of cyclin D1b function in spe-
cific tissues. For AR, it has been established that cyclin
D1b is significantly altered in its ability to modulate
receptor function, and as discussed below, this disparate
action has consequence in prostate cancer cells [37].
Cyclin D1 and cyclin D1b effects on AR activity in prostate 
cancer cells
Prostate cancer cells are unique amongst tumors types in
that they are dependent on AR function for growth and
survival [82]. The androgen dependence of prostate can-
cer cells is exploited in treatment of disseminated prostate
cancers, wherein ablation of AR activity (through either
ligand depletion and/or through the use of AR antago-
nists) is the first line of therapeutic intervention [83-
85,82,86]. These therapies are initially effective, and
induce a mixed response of cell cycle arrest or apoptosis of
the prostate cancer cells, regardless of whether or not the
tumor remains organ-confined. However, recurrent
tumors form within a median time of 2–3 years, and no
effective treatment has been identified to treat recurrent
disease. Interestingly, analyses of recurrent tumors
revealed that in the great majority of therapy-resistantCell Division 2006, 1:15 http://www.celldiv.com/content/1/1/15
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tumors, AR has been re-activated, as achieved through
either AR amplification, AR mutation, ligand-dependent
AR activation, and/or through excessive production of AR
co-activators [82]. Moreover, deregulation of AR activity
has been validated in tumor models to be sufficient for
therapeutic bypass [87,88]. Together, these observations
indicate that AR is a critical determinant for prostate can-
cer growth and progression.
AR stimulates prostate cancer cell growth through its abil-
ity to stimulate gene expression [89,90]. Although the
proximal targets that elicit this mitogenic response have
yet to be identified, AR activation results in accumulation
of D-type cyclins, including both cyclin D1 and cyclin D3
[91]. Functional studies revealed that induction of D-type
cyclins resulted in enhanced CDK4 activity and RB phos-
phorylation, as expected based on the ability of androgen
to induce G1-S progression. Forced expression of full-
length cyclin D1 (and/or CDK4) under conditions of
androgen ablation failed to bypass cell cycle arrest,
whereas viral oncoprotein induced RB inactivation
strongly promoted androgen-dependent cellular prolifer-
ation, thus indicating that cyclin D1 is not sufficient to
induce cell cycle progression in this cell type [91,92]. By
contrast, studies performed in the presence of androgen
indicated that accumulated cyclin D1 markedly attenuates
cellular proliferation in this cell type, dependent on the
ability of cyclin D1 to modulate AR function [93]. Thus, a
feedback model has been proposed, wherein cyclin D1
elicits a pro-proliferative, CDK4 dependent function to
stimulate cell cycle progression after androgen stimula-
tion, and accumulated cyclin D1 serves to modulate the
strength and duration of the androgen response through
attenuating AR function (Figure 3A). It is notable that
unlike many of the other nuclear receptors (e.g. ER) the
AR is not degraded after ligand stimulation, but is actually
stabilized by ligand binding [94]. Thus, this intrinsic
mechanism of feedback control may be important for
titering the mitogenic response. Strikingly, the cyclin D1b
variant is compromised for this feedback control mecha-
nism, and this disparate action is attributed to its altered
ability to regulate AR function.
Full-length cyclin D1 utilizes multiple mechanisms to
modulate AR activity, and these functions have been well
described. First, it has been shown that the principal cyc-
lin D1 binding site resides in an N-terminal region of the
AR that modulates ligand-dependent conformational
changes (the 23FxxLF27) motif [95]. In response to ligand,
the FxxLF motif docks into a C-terminal, hydrophobic
cleft of the receptor, and this "N-C terminal interaction" is
important for both AR activity and chromatin association.
Cyclin D1 binding strongly reduces N-C interaction, and
this passive mechanism underlies a significant portion of
cyclin D1 repressor function. Second, cyclin D1 employs
HDACs to modulate AR activity, and cyclin D1 repressor
function is reversed through HDAC inhibition [93]. Cyc-
lin D1 associates with HDAC3 in prostate cancer cells,
through a repressor domain motif that is required and suf-
ficient for AR modulation [96]. Lastly, it has been pro-
posed that cyclin D1 can compete for P/CAF binding to
AR, thus precluding co-activator function [97]. However,
this observation was not confirmed in all model systems
analyzed [93]. The net result of these actions is down-reg-
ulation of AR function, as demonstrated by slowed cell
cycle progression and down-regulation of endogenous
PSA (prostate specific antigen) expression, an AR target
gene utilized clinically to monitor prostate cancer growth
and recurrence [98]. The repressor functions occur at stoi-
chiometric levels of AR and cyclin D1, thus indicating that
modest elevations of cyclin D1 can have significant effects
on prostate cancer growth.
Cyclin D1b maintains the repressor domain required for
each of these cyclin D1 functions and indeed, the ability
to block ligand induced N-C interaction and to recruit
HDACs to the AR complex is generally conserved in the
cyclin D1b variant [37]. However, functional analyses
revealed that cyclin D1b is selectively compromised for
AR regulation, dependent on the target gene analyzed.
Compared to full-length cyclin D1, the cyclin D1b variant
was significantly deficient in its ability to repress AR-
dependent expression of the prostate specific antigen
(PSA) mRNA expression in prostate cancer cells, a target
gene used clinically to monitor prostate growth and pro-
gression. Similar effects were observed in the analyses of
other AR target genes (e.g. Slp, sex-limited protein),
whereas no distinctions were observed using the non-AR
specific MMTV locus. The most striking disparity in func-
tion between the two cyclin D1 proteins in the context of
prostate cancer was observed using cellular proliferation
as an endpoint. Consistent with the negative feedback
model, full-length cyclin D1 markedly inhibited cell cycle
progression in AR dependent (but not AR negative) pros-
tate cancer cells. However, cyclin D1b was completely
ineffective at attenuating the proliferative response, and in
fact stimulated cellular proliferation in the AR positive
cells. Collective analyses of cyclin D1b mediated AR regu-
lation indicated that the altered AR regulatory capacity of
cyclin D1b at least partially underpins its ability to induce
cell cycle progression in this cell type (Figure 3B), and
likely acts in concert with the heightened oncogenic
capacity of cyclin D1b revealed in NIH3T3 studies. These
data suggest that cyclin D1b may hold multiple oncogenic
functions in prostate cancer cells, and predict that the reli-
ance of this tumor cell type on AR function could result in
selective pressure to produce the cyclin D1b isoform.
Whether these predictions hold true will require deeper
consideration of cyclin D1 isoform expression and/orCell Division 2006, 1:15 http://www.celldiv.com/content/1/1/15
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function during prostate cancer development and pro-
gression.
Cyclin D1b and prostate cancer
To date, few studies have assessed the role of cyclin D1 in
prostate cancer. While cyclin D1 is frequently amplified
and/or overexpressed in breast cancer [71], cyclin D1
overexpression is rarely observed in prostatic tumors [99].
When excessive cyclin D1 has been reported, this parame-
ter has no significant independent prognostic value, and
is predictive of poor prognosis only in the presence of
high cyclin A (thus indicative of a high proliferative index)
[99]. In a comparative study of local disease, few tumors
showed cyclin D1 expression (11% of tumors showed
greater than 20% positive nuclei), whereas bone metas-
tases showed increased frequency of cyclin D1 expression
(68%), thus indicating that the role of cyclin D1 may be
altered in distant metastases [100]. Still, no correlation
with pathological grade or recurrent tumor formation was
observed in these data sets. In animal models, cyclin D1 is
D-type cyclins regulate androgen receptor function in prostate cancer cells Figure 3
D-type cyclins regulate androgen receptor function in prostate cancer cells. A) Cyclin D1 is induced following 
androgen stimulation, and acts through discrete mechanisms to both promote cell cycle progression and attenuate androgen 
receptor (AR) activity (left panel). These control mechanisms are hypothesized to modulate the strength and duration of the 
androgen response (right panel). B) The cyclin D1b variant harbors enhanced oncogenic function as compared to cyclin D1, 
and interrogation of cell cycle function suggests that cyclin D1b may impinge on additional factors to promote proliferation. In 
the context of prostate cancer, compromised ability of cyclin D1b to modulate AR function may disrupt modulation of the 
androgen response, and yield an enhanced proliferative response.Cell Division 2006, 1:15 http://www.celldiv.com/content/1/1/15
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downregulated or sequestered in the cytoplasm of
advanced tumors, thus indicating that the AR regulatory
function may be lost in this disease [101]. Recent reports
indicate that knockdown of AR expression (via siRNA)
results in induction of cyclin D1 expression [102], thus
indicating that the pressure to restrain cyclin D1 expres-
sion may be lifted upon AR elimination. These collective
data indicate that the role of cyclin D1 in prostate cancer
is complex, and that alterations in full-length cyclin D1
expression and localization may have both positive and
negative effects on tumor growth.
Recently it was revealed that the cyclin D1b variant is
highly expressed in localized prostate cancer, as compared
to matched normal tissue [37]. Lymph node metastases of
prostate cancer also maintained cyclin D1b expression.
Given the relative poor efficacy of cyclin D1b in titering
AR function, high cyclin D1b expression may render a
mechanism whereby prostate cancer cells may promote
CDK4 activity (and/or other pro-proliferative targets uti-
lized by cyclin D1b) while concurrently evading mecha-
nisms to modulate the AR dependent growth response.
Based on this hypothesis, one might speculate that spe-
cific contextual variables (e.g. AR expression and depend-
ence) may distinguish cyclin D1b action in individual cell
types (e.g. prostate cancer cells versus NIH3T3 cells). Iden-
tification of these potential variables will afford a deeper
understanding of cyclin D1b oncogenic potential and
indeed are requisite to clarify the biological consequence
of cyclin D1b in individual tumor types. Although the
sample size examined was small, preliminary data dem-
onstrated that cyclin D1b was also highly expressed in
prostatic intraepithelial neoplasias (PIN lesions), which
are thought to be precursors of adenocarcinoma. These
observations suggest that cyclin D1b expression may be
induced early in tumor development, and may participate
in the transformation of prostatic epithelial cells. Addi-
tional investigation in this tumor type will be needed to
segregate the relative impact of transcriptional versus cell
cycle and/or oncogenic effects of cyclin D1b on tumor
growth and progression.
Conclusions and future considerations
The cyclin D1b variant exhibits unique properties that
may underlie its enhanced oncogenic potential. First, cyc-
lin D1b is a constitutively nuclear protein, and has
enhanced transformation capacity in tested model sys-
tems. Second, cyclin D1b is a poor catalyst of CDK4 activ-
ity in cell systems analyzed to date, thus suggesting that
cyclin D1b utilizes non-canonical mechanisms to induce
its oncogenic function. Third, cyclin D1b retains the abil-
ity of full-length cyclin D1 to modulate the action of some
(but not all) transcription factors, and this differential
function may hold consequence in selected tumor types.
In prostate cancer, the disparate ability of cyclin D1b to
govern AR function appears to hold significance for both
the control of transcriptional regulation and cellular pro-
liferation.
Despite these advances in delineating cyclin D1b func-
tion, many critical questions remain to be addressed. First,
what are the factors that govern cyclin D1b production? A very
limited set of variables have been shown to influence the
aberrant splicing event (e.g. the G/A870 polymorphism,
SWI/SNF function), but it is clear that additional factors
must assist in controlling the splicing decision. Second,
what function(s) of cyclin D1b underlie its enhanced trans-
forming potential? Possibilities to be considered include
novel protein associations, novel substrate recognition,
unexpected effects of sustained nuclear localization, and/
or loss of responsiveness to anti-mitogenic signals. Third,
what is the relative impact of cyclin D1b on transcriptional reg-
ulation? Early indications suggest that in hormone
dependent cancers that cyclin D1b transcriptional effects
are distinct, but the tissue specific effects of cyclin D1b on
gene expression have been remarkably understudied.
Fourth, what is the overall biological consequence of cyclin D1b
expression in cancer? The impact of cyclin D1b is likely to
be cell type specific, subject to relative stoichiometry with
full-length cyclin D1, and dependent on the availability of
cofactors to mitigate cellular response. Tissue specific dis-
tribution, relative patterns of expression in tumor and
matched normal tissue should also be considered, so as to
sort out the timing and impact of cyclin D1b production.
In sum, analyses of cyclin D1b expression in a multitude
of tumor types underscores the potential importance of
cyclin D1b for tumor development and/or progression,
and rigorous investigation of this novel oncogene is nec-
essary to reveal the divergent mechanisms by which cyclin
D1b elicits its potent effect in tumor cells.
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